CORRECTION -- Precipio continues to sign up and onboard HemeScreen™ customers
March 07, 2023 12:49 ET
|
Precipio, Inc.
NEW HAVEN, Conn., March 07, 2023 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Precipio, Inc. (NASDAQ: PRPO), please note that the 5th paragraph should read...
Precipio continues to sign up and onboard HemeScreen™ customers
March 07, 2023 12:00 ET
|
Precipio, Inc.
NEW HAVEN, Conn., March 07, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) continues to convert its sales pipeline into HemeScreen customers, with an...
Precipio to distribute HemeScreen® through Fisher Healthcare channel
July 20, 2022 10:30 ET
|
Precipio, Inc.
NEW HAVEN, Conn., July 20, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced that it has entered into an agreement with Fisher Healthcare,...
Precipio Launches New HemeScreen Panel for AML, with an unparalleled 4-hour turnaround-time
May 10, 2021 10:30 ET
|
Precipio, Inc.
NEW HAVEN, Conn., May 10, 2021 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that it has launched a new, four-hour Acute Myeloid Leukemia (AML)...
Precipio Launches its Proprietary HemeScreen™ AML (Acute Myeloid Leukemia) Molecular Panel
September 22, 2020 10:30 ET
|
Precipio, Inc.
NEW HAVEN, Conn., Sept. 22, 2020 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that it has launched its HemeScreen™ AML (Acute Myeloid...